Clinical trials: Autoimmune Diseases, open to volunteers
Systemic Lupus Erythematosus, Rheumatoid Arthritis
A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases
The purpose of this study is to learn about the safety and effects of the study medication called PF-08154225 for the potential treatment of autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Idiopathic Inflammatory Myositis, Systemic Sclerosis
- Trial name
- NCT07782450
- Testing
- PF-08154225
- Volunteers
- 54 people
- Sponsor
- Pfizer
Myositis, Dermatomyositis
Environmental Risk Factors for the Anti-synthetase Syndrome
Background: Like other complex diseases, autoimmune diseases are the result of numerous causes, including genetic and environmental factors.
- Conditions
- Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis
- Trial name
- NCT01276470
- Where
- 8 sites in United States
- Volunteers
- 580 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Multiple Sclerosis
A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice
This study aims to generate real-world evidence on the clinical effectiveness and economic burden of ofatumumab (OMB) versus ocrelizumab (OCR) in patients diagnosed with multiple sclerosis (MS) in the United States (US).
- Trial name
- NCT07779460
- Where
- United States
- Volunteers
- 7,466 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Renal Disease
Systemic Lupus Erythematosus and Chlordecone Impregnation in Martinique
Chlordecone, an organochlorine pesticide, was widely used on banana farms in the French West Indies. Studies by Inserm and health authorities have confirmed the contamination of the food chain and the majority of the population…
- Trial name
- LUNEK (NCT06365359)
- Testing
- Blood sample for analysis of plasma of organochlorine pesticides concentration, Blood sample for cell collection
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital Center of Martinique
Multiple Sclerosis, Parkinson Disease
Biomarkers of Synaptic Damage in Multiple Sclerosis
A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neurology Unit.
- Conditions
- Multiple Sclerosis, Parkinson Disease, Amyotrophic Lateral Sclerosis, Alzheimer Disease
- Trial name
- NCT03217396
- Testing
- lumbar puncture
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Neuromed IRCCS
Diabetes (Insulin-requiring, Type 1 or Type 2)
APP-MNT: App-Enhanced Medical Nutrition Therapy on Glycemic Outcomes and Quality of Life
The purpose of the study is to see if using a diabetes app along with nutrition counseling from a registered dietitian nutritionist can help improve blood sugars and cholesterol levels, quality of life, physical activity, and…
- Trial name
- App-MNT (NCT07773779)
- Testing
- Undermyfork Care App, Usual Care
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Sclerosis
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
The primary objectives of the study are to estimate the risk of major congenital malformations (MCMs) in infants born to women with multiple sclerosis (MS) who were exposed to diroximel fumarate (DRF) at any time from 2 weeks…
- Trial name
- NCT05658497
- Testing
- Diroximel Fumarate, Avonex, Tysabri
- Where
- 8 sites in United States, Australia and 5 more
- Volunteers
- 908 people
- Sponsor
- Biogen
Meibomian Gland Dysfunction, Dry Eye Syndromes
Ocular Surface Changes and Meibomian Gland Dysfunction in Rheumatologic Patients
This observational study aims to assess the frequency and severity of Meibomian Gland Dysfunction (MGD) and associated ocular surface changes in patients with systemic autoimmune rheumatic diseases compared with healthy…
- Conditions
- Meibomian Gland Dysfunction, Dry Eye Syndromes, Rheumatoid Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT07810569
- Volunteers
- 150 people
- Sponsor
- Assiut University
Multiple Sclerosis (MS) Secondary Progressive
Senolytics for Secondary Progressive MS
This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS and whether treatment improves physical and thinking abilities.
- Trial name
- NCT07270120
- Testing
- Dasatinib and quercetin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University
Type 1 Diabetes, Hypoglycemia
Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes
The objectives of this study are to examine how sex hormones (use of hormonal birth control, menstrual cycle phase) impact glycemic control among women with type 1 diabetes (T1D), and to test adjustments to insulin dosing and…
- Conditions
- Type 1 Diabetes, Hypoglycemia, Hyperglycaemia Due to Type 1 Diabetes Mellitus, Menstruation Disturbances
- Trial name
- MERIT (NCT06297980)
- Testing
- Personalized modifications to treatment to address menstrual cycle effects on glycemia
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Colorado, Denver
Adrenal Insufficiency, Polymyalgia Rheumatica
Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency
In this double-blinded randomised placebo-controlled clinical trial, the aim is to determine the effect of supplemental hydrocortisone compared with placebo during mild to moderate physical or mental stress on health related…
- Conditions
- Adrenal Insufficiency, Polymyalgia Rheumatica, Giant Cell Arteritis
- Trial name
- RESCUE (NCT05435781)
- Testing
- Hydrocortisone
- Where
- 3 sites in Denmark
- Volunteers
- 250 people
- Sponsor
- Marianne Christina Klose
Type 1 Diabetes, Type 1 Diabetes (T1D)
Study of IMC-S118AI in Type 1 Diabetes
This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens.
- Conditions
- Type 1 Diabetes, Type 1 Diabetes (T1D), Diabetes Type 1
- Trial name
- NCT07493122
- Testing
- IMC-S118AI
- Volunteers
- 154 people
- Sponsor
- Immunocore Ltd
Diabetes Mellitus, Type 1
Bioavailability, Biopotency and Food Effect Study of SCD0503 Compared to Subcutaneous Regular Human Insulin
Reason for the study The participants have been diagnosed with type 1 diabetes and are being treated with standard insulin therapy.
- Trial name
- NCT07634770
- Testing
- oral insulin, subcutaneous insulin
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Lupus Nephritis
CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis
A Clinical Study of the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis.
- Trial name
- NCT06785519
- Testing
- CD19/BCMA Lupus Nephritis Targeted CAR T-cells injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- He Huang
Generalized Myasthenia Gravis, Anti-AChR Antibody Positive
Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.
- Trial name
- NCT06967480
- Testing
- Ravulizumab
- Where
- 23 sites in Italy
- Volunteers
- 40 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Diabetes type1, Diabetes Mellitus, Type 1
Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes: A Pragmatic SMART
This study is designed to compare two behavioral approaches to reduce diabetes distress ("the expected burdens, concerns, fears, and threats that arise from the challenges of living with diabetes") in adults with type 1 diabetes.
- Conditions
- Diabetes type1, Diabetes Mellitus, Type 1, Diabetes, Autoimmune, Diabetes Mellitus
- Trial name
- ChargeUp (NCT06405373)
- Testing
- ReCharge, TakeCharge
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of North Carolina, Chapel Hill
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Chronotype of Patients With Diabetes and Effect on Glycaemic Control
The aim of this study is to explore the associations between chronotype and glycaemic control, cardiometabolic health and other lifestyle factors.
- Trial name
- CODEC (NCT02973412)
- Where
- United Kingdom
- Volunteers
- 3,447 people
- Sponsor
- University of Leicester
Lupus Erythematosus, Systemic
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
The purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks…
- Trial name
- GARDENIA-SLE (NCT07438496)
- Testing
- Nipocalimab, Standard of care treatment
- Where
- 272 sites in United States, Argentina and 31 more
- Volunteers
- 600 people
- Sponsor
- Janssen Research & Development, LLC
H. Pylori, SLE - Systemic Lupus Erythematosus
Associating Gastric Infection With Autoimmune Flare Severity in an Egyptians
A cross-sectional, observational study aims to evaluate the relationship between Helicobacter pylori infection and disease activity in patients diagnosed with systemic lupus erythematosus (SLE), using a combination of structured…
- Trial name
- NCT07157202
- Volunteers
- 115 people
- Sponsor
- Assiut University
Relapsing Remitting Multiple Sclerosis (RRMS)
Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans.
- Trial name
- iPROACT-MS (NCT07318129)
- Testing
- Indole-3-propionic acid (IPA)
- Where
- Denmark
- Volunteers
- 220 people
- Sponsor
- Glostrup University Hospital, Copenhagen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.